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The candidate tumour-suppressor gene, LUCA-15/RBM5/H37, maps to the lung cancer 
tumour-suppressor locus 3p21.3. The LUCA-15 gene locus encodes at least four 
alternatively spliced transcripts that have been shown to function as regulators of 
apoptosis, a fact which may have major significance in tumour regulation. This review 
highlights recent evidence that further implicates the LUCA-15 locus in the control of 
apoptosis and cell proliferation, and focuses on the observations that confirm the 
tumour-suppressor activity of this gene. 
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INTRODUCTION 
The molecular control of cancer is complex. The dysregulation of a whole range of normal cellular 
systemic processes contributes to the development of cancer. These processes include cell 
proliferation[1], cell-cell communication[2], DNA repair[3], chromosome stability[4], cell motility[5,6], 
apoptosis[7], and others. Despite impressive progress in recent years in understanding the molecular basis 
of cancer, many crucial genes remain to be identified. One or more such genes are located at the human 
chromosomal locus 3p21.3, which is strongly associated with lung cancer and many other cancers 
including head and neck, renal, breast, and female genital tract[8,9]. More than 90% of freshly 
microdissected primary lung cancers display loss of heterozygosity (LOH) of 3p21.3, and the fact that no 
single locus of this region appears to be consistently affected by LOH suggests that the region harbours 
more than one tumour-suppressor gene (TSG)[10,11]. The search for TSGs in this region has, therefore, 
been the focus of extensive investigations over the past 10 years, and many genes mapping to this region 
have been cloned[12,13,14].  
LUCA-15 is among the 35 genes located within the 370-kb, overlapping, lung cancer, homozygous 
deletion region at 3p21.3[12]. Timmer et al. and Oh et al. reported the cloning of the same gene, naming it 
RBM5 (RNA-binding motif protein 5) and H37, respectively[8,9]. In this mini-review, the effects of 
LUCA-15 are discussed in the context of regulation of apoptosis, cell proliferation, and involvement in 
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malignancy. The growing literature on this subject strongly suggests that LUCA-15 plays an important 
role in the regulation of cell proliferation, apoptosis, and cancer, thus elucidation of its mechanisms of 
action should advance our understanding both of apoptosis and of oncogenesis. 
LUCA-15: AN RNA-BINDING PROTEIN 
LUCA-15 was initially cloned as a putative TSG mapping to 3p21.3[8,12] and encoded a number of 
alternative splice variants[23,25,26]. Full-length LUCA-15 mRNA contains an open reading frame of 815 
amino acids and is translated in vivo into a predicted protein product of ~90 kDa[8]. It was designated 
RBM5 due to the presence of two RNA-binding domains (RBD), also recognised as RNA recognition 
motif (RRM), within its primary sequence. Other functional motifs in the LUCA-15 structure include two 
putative zinc-finger DNA binding motifs, two bipartite nuclear localisation signals, and a G-patch domain 
(a conserved domain in eukaryotic RNA-processing proteins and type D retroviral polyproteins)[15], 
suggesting a role for LUCA-15 in RNA processing and its localisation to the nucleus. The N-terminal 
fragment of human LUCA-15 containing the RNA binding domain[16] and an epitope-tagged LUCA-15 
protein were found to interact preferentially with poly (G) RNA homopolymer in vitro[17]. In addition, 
the C-terminal region of LUCA-15 contains several domains including a glutamine rich domain (362-
385), which is thought to serve as protein–protein interaction site in certain RNA- and DNA-binding 
proteins[17]. 
A number of proteins having one or more RRM domains have been identified (reviewed by 
Sutherland et al.[29]). Those include RBM6, an immediate telomeric neighbour of RBM5, also a 
candidate TSG, which shares 30% amino acid sequence identity, indicating that they are likely to be part 
of the same gene family and arose through gene duplication[7,8,16,19,20,21]. Another RBM protein that 
shares high homology with RBM5 (53% at the amino acid level) is RBM10. The RBM10 gene is located 
on the X chromosome at p11.23[39]. No function has yet been determined for RBM10, however, its high 
sequence homology at the amino acid level with RBM5 and RBM6 suggests that it may play an important 
role in apoptosis. Another protein identified with RBM domains is RBM3, which is reported to suppress 
polyglutamine-induced apoptosis[40]. The observation that some RBM proteins display apoptotic 
modulatory effects raises the possibility that their apoptotic function could be related to their function as 
RNA-binding proteins. Other members of the RNA-binding protein family are already reported to be 
involved in various aspects of RNA synthesis, alternate splicing, RNA editing, and metabolism. Important 
information has emerged that defines the molecular mechanisms by which RNA-binding proteins 
recognise specific RNA sequences and influence the processing and function of RNA 
molecules[27,31,32]. The importance of these interactions was also highlighted by the discovery that 
RNA-binding protein abnormalities are found in several human genetics disorders[33,34]. 
REGULATION OF APOPTOSIS AND CELL PROLIFERATION BY LUCA-15 CDNA 
FAMILY 
LUCA-15 is ubiquitously expressed in human tissues[16]. Its level is reported to be high in the adult 
thymus and low in the foetal thymus, indicating that its expression can be developmentally regulated[16]. 
The LUCA-15 gene encodes a number of alternative splice variants, as identified by reverse transcription-
polymerase chain reactions[29,30]. Although the LUCA-15 gene has not been shown to have an increased 
mutation rate in cancers, a number of lines of evidence do suggest its involvement in apoptosis and in cell 
cycle regulation. LUCA-15 is reported to be down-regulated in RAS-transformed Rat-1 cells, in samples 
from breast cancer[18], in human schwannomas[38], and in ~75% of primary lung cancers 
specimens[36]. In addition, overexpression of LUCA-15 in human fibrosarcoma HT1080 cells suppressed 
cell growth[18]. Finally, LUCA-15 was one of the antigens identified by autologous antibody in patients 
with renal carcinoma[22]. 
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LUCA-15’s involvement in apoptosis and malignancy has been the focus of many recent studies, with 
all results converging on a role for LUCA-15 as a TSG. The first piece of evidence that supports a 
possible role for LUCA-15 in apoptosis derives from the studies performed by Sutherland and 
colleagues[23]. Using an episomal retrieval, functional expression, cloning system[23], a 326-bp bone 
marrow cDNA fragment (termed Je2; Accession No. AF107492), which strongly inhibits Fas-mediated 
apoptosis in Jurkat T-cells, was identified[23]. Je2 lies within an intron of the LUCA-15 gene (Accesssion 
No.U23946), in the opposite orientation to LUCA-15 transcription[12]. Stable expression of Je2 in 
another human T-cell line CEM-C7 produced marked inhibition of Fas-mediated apoptosis and conferred 
protection from apoptosis induced by other stimuli (Fig. 1)[24]. Since Je2 is complementary to part of the 
LUCA-15 locus, it is likely to suppress apoptosis in the CEM-C7 cell line through a direct antisense 
effect on LUCA-15 RNA. Interestingly, the LUCA-15 polypeptides present are altered significantly in 
CEM-C7–Je2 stable clones[35], indicating that Je2 might function to inhibit apoptosis by interfering with 
the processing of LUCA-15 transcripts.  
 
FIGURE 1. Je2 overexpression inhibits CD95-, TNFα-, and dexamethasone-mediated cell death. CEM-
C7 cells were stably transfected with pcDNA3 vector alone or pcDNA3-Je2. Cells (2 × 105 cells/ml) were 
incubated in the presence of 5 ng/ml anti-CD95, 50 ng/ml TNFα, and 10 μM dexamethasone for 48 h. The 
percentage of dead cell number was determined by nigrosin dye exclusion. 
Other evidence has been obtained that demonstrates that LUCA-15 is also a negative regulator of cell 
proliferation. Overexpression of the full-length LUCA-15/RBM5 in CEM-C7 and Jurkat T-cell lines 
suppressed cell proliferation both by inducing apoptosis and by inducing cell cycle arrest in G1 (Fig. 
2A)[25,30]. Consistently, LUCA-15 overexpression also inhibited human lung cancer cell growth (A549 
nonsmall cell lung cancer line) by increasing apoptosis and inducing cell cycle arrest in G1[37]. This 
inhibition of cell growth was reported to be associated with decreased cyclin A and phosphorylated RB, 
and an increase in the level of the proapototic protein Bax[37]. In addition, introducing LUCA-15 into 
breast cancer cells that had 3p21-22 deletions reduced both anchorage-dependent and -independent 
growth. LUCA-15 also is reported to suppress anchorage-dependent and -independent growth in A9 
mouse fibrosarcoma cells, and to inhibit their tumour-forming activity in nude mice[36]. Most 
interestingly, LUCA-15 was one of the 9 genes down-regulated in metastasis and it has been included in 
the 17 common gene signature associated with metastasis identified in multiple solid tumour types[41]. 
Solid tumours carrying this gene expression signature had high rates of metastasis and poor clinical 
outcomes[41]. 
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FIGURE 2. (A) LUCA-15/RBM5 is capable of inducing cell cycle arrest in G1-M and apoptosis. DNA 
content from CEM-C7/pcDNA3 and CEM-C7/pcDNA3-RBM5 was quantified by propidium iodide staining 
of fixed cells. (B) LUCA-15Δ6 overexpression results in an increase in cells in S and G2/M phases, and a 
concomitant decrease in G1 cells, producing an increase in proliferation rate.  
Another convincing line of reasoning derives from the fact that splice variants of the LUCA-15 gene 
have been shown to function as regulators of apoptosis[23]. Both alternative RNA splicing and antisense 
transcription occur at the LUCA-15 gene locus[23]. LUCA-15 splice variants display antagonistic 
properties that include promotion of apoptosis and inhibition of proliferation by transcripts encoding full-
length LUCA-15 and another alternative splice variant (clone 26)[23,30]. In direct contrast, LUCA-15Δ6, 
a variant lacking exon 6 and producing a truncated protein, is up-regulated in some T-cell leukaemic lines 
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and inhibits CD95-mediated apoptosis as well as accelerating proliferation (Fig. 2B)[30]. These 
observations suggest that changes in the level of expression of LUCA-15 or in the processing of its 
mRNA have profound consequences for cellular behaviour. 
EFFECTS OF LUCA-15 MODULATION ON THE EXPRESSION OF APOPTOSIS AND 
CELL CYCLE GENES 
In order to investigate the molecular mechanisms of action of LUCA-15, microarray-based analysis of 
changes in gene expression caused by the modulation of the level of LUCA-15 were carried out. Among 
5603 genes on cDNA microarray, 35 genes, well known for their roles in the cell cycle as well as in 
apoptosis, were found to be differentially expressed as a result of LUCA-15 overexpression in CEM-C7 
cells[42]. Some of the LUCA-15 modulated genes include a number of cyclin-dependent kinase 
complexes, most notably CDK2, required during G1/S phase, and CDK inhibitor A, reported to be deleted 
in many cancers[42]. Three putative oncogenes are down-regulated by LUCA-15, again consistent with 
the role for LUCA-15 as a TSG. These are Pim-1, a serine/threonine kinase, ITPA (inosine triphosphate 
pyrophosphatase), and amplified in breast cancer 1 (AIB1)[42,43,44,45]. Other functionally important 
genes modulated by LUCA-15 are well established to play specific antiapoptotic roles, such as AIP3 
(BIRC4), cIAP2 (BIRC3, MIHC), Mcl-1, a member of the Bcl-2 family of apoptosis suppressors, and 
TRAF1, supporting a role for LUCA-15 in apoptosis[42]. Other genes up-regulated by LUCA-15 include 
Stat5b, annexin I, and bone morphogenetic protein 5 (BMP5), implicated in apoptosis, 
immunosuppression, and organ development, respectively[42,46,47,48]. The consistent and substantial 
effects on such functionally important genes imply that LUCA-15 plays a critical role in the control of the 
cell fate.  
Down-regulation of the LUCA-15 gene, achieved by the overexpression of Je2, also resulted in 
reciprocal changes of six key genes affected by LUCA-15, but in the reverse direction (Table 1)[42]. 
These genes include Stat5b, IAP homolog C, annexin I, AIB1, Pim1, and CDK2. The appearance of these 
complementary changes caused by LUCA-15 and Je2 provides more evidence that both these important 
genes are genuinely affected by LUCA-15 and that these effects are produced at physiological levels of 
LUCA-15. 
TABLE 1 
Reciprocal Changes of Six Key Genes as a Result of LUCA-15 and Je2 Overexpression  
(Microarray-based analysis) 
Gene 
Description 
Cluster ID Fold Change in RBM5 
Overexpressing Clones 
Fold Change in Je2 
Overexpressing Clones 
Stat5b 
BMP-5 
cIAP2 
AIB1 
Annexin I 
CDK2 
s.244613 
Hs.1104 
Hs.1277991 
Hs.225977 
Hs.78225 
Hs.310540 
4.3 (↑) 
4 (↑) 
6 (↓) 
3.26 (↓) 
5.5 (↓) 
2.5 (↓) 
6.7 (↓) 
4.4 (↓) 
5 (↑) 
2 (↑) 
2.8 (↑) 
13 (↑) 
(↓) Decrease; (↑) increase. 
Taken together, all of the foregoing evidence is consistent with the concept that LUCA-15 plays an 
important role in the regulation of cell proliferation and apoptosis, and supports a role for LUCA-15 as 
one of the 3p21.3 TSGs. LUCA-15 belongs to a large family of related proteins that have diverse 
functions in the regulation of gene expression[26]. Members of this RNA-binding protein superfamily are 
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involved in various aspects of RNA synthesis, alternate splicing, RNA editing, and metabolism[26]. In 
addition, LUCA-15 contains a glutamine-rich domain, which is thought to serve as protein-protein 
interaction site. Thus, it is likely that LUCA-15 may regulate the activity of genes responsible for the 
control of the cell cycle and apoptosis by both transcriptional and post-transcriptional mechanisms. 
Identification of the RNA and proteins that interact with LUCA-15 should provide more information into 
its function.  
CONCLUSION 
A number of genes, including p53, are currently accepted as bona fide tumour suppressors, whose 
mutation or deletion is associated with tumourigenesis in human cancers[28]. The ability of LUCA-15 to 
inhibit the growth of transformed cells fulfills one of the criteria for a tumour suppressor. In addition, 
LUCA-15 is located at an important site on chromosome 3, a region highly susceptible to aberrant 
chromosomal rearrangement and deletions, suggesting the presence of TSG at this locus[7,8,9]. The 
simultaneous changes in proliferation and inhibition of apoptosis brought about by dysregulation of the 
LUCA-15 locus are therefore likely to be of major significance in cancer development, and provide a 
foundation to further investigate the role of LUCA-15 in oncogenesis, to define the LUCA-15 role as a 
bona fide TSG, and to evaluate its potential as a therapeutic or diagnostic target in cancer.  
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